Zymeworks (ZYME) Free Cash Flow (2021 - 2026)
Zymeworks (ZYME) posted Free Cash Flow of -$45.8 million for Q1 2026, down 322.68% sequentially from -$10.8 million in Q4 2025, and down 1238.53% YoY from $4.0 million in Q1 2025.
Powered by 
Analysis
Zymeworks (ZYME) Free Cash Flow (2021 - 2026) Analysis & Trends
Zymeworks has reported Free Cash Flow for 6 years, with the latest figure at -$45.8 million in Q1 2026.
- Quarterly Free Cash Flow fell 1238.53% year-over-year to -$45.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$76.9 million (up 1.13% YoY) and the FY2025 annual result came in at -$34.5 million, up 69.19% from the prior year.
- Free Cash Flow fell to -$45.8 million in Q1 2026 per ZYME's latest filing, from -$10.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $327.8 million in Q4 2022 and troughed at -$83.6 million in Q1 2023.
- A 5-year average of -$9.9 million and a median of -$31.8 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2026: Free Cash Flow jumped 745.43% in 2022, then sank 1238.53% in 2026.
- Over 5 years, Free Cash Flow stood at $327.8 million in 2022, then sank by 95.14% to $15.9 million in 2023, then slumped by 362.57% to -$41.8 million in 2024, then surged by 74.08% to -$10.8 million in 2025, then sank by 322.68% to -$45.8 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$45.8 million, -$10.8 million, and -$31.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | -31.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -31.95 Mn |
| Mar 31, 2026 | -45.93 Mn |
| Dec 31, 2025 | -10.84 Mn |
| Sep 30, 2025 | -31.82 Mn |
| Jun 30, 2025 | 11.62 Mn |
| Mar 31, 2025 | -3.49 Mn |
| Dec 31, 2024 | -41.82 Mn |
| Sep 30, 2024 | -6.78 Mn |
| Jun 30, 2024 | -25.59 Mn |
| Mar 31, 2024 | -37.86 Mn |
| Dec 31, 2023 | 13.58 Mn |
| Sep 30, 2023 | -43.60 Mn |
| Jun 30, 2023 | -7.20 Mn |
| Mar 31, 2023 | -83.58 Mn |
| Dec 31, 2022 | 327.01 Mn |
| Sep 30, 2022 | -74.00 Mn |
| Jun 30, 2022 | -57.49 Mn |
| Mar 31, 2022 | -59.57 Mn |
| Dec 31, 2021 | -55.29 Mn |